Cytosorbents Co. (NASDAQ:CTSO) Short Interest Down 5.7% in September

Cytosorbents Co. (NASDAQ:CTSO) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,330,000 shares, a decrease of 5.7% from the September 15th total of 1,410,000 shares. Based on an average daily volume of 91,700 shares, the short-interest ratio is currently 14.5 days.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CTSO. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Wednesday, August 14th. StockNews.com began coverage on Cytosorbents in a report on Thursday. They set a “hold” rating for the company. Finally, EF Hutton Acquisition Co. I upgraded Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th.

Institutional Trading of Cytosorbents

Several large investors have recently made changes to their positions in CTSO. Key Client Fiduciary Advisors LLC grew its stake in shares of Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares during the period. Atomi Financial Group Inc. acquired a new stake in shares of Cytosorbents in the 3rd quarter valued at about $51,000. CM Management LLC grew its stake in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares during the period. Sargent Investment Group LLC lifted its position in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Finally, Avenir Corp lifted its position in Cytosorbents by 4.0% in the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after acquiring an additional 121,294 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Stock Performance

Shares of Cytosorbents stock opened at $1.12 on Thursday. The company has a current ratio of 2.12, a quick ratio of 1.71 and a debt-to-equity ratio of 0.82. The business has a 50-day moving average price of $1.14 and a two-hundred day moving average price of $1.00. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $2.15. The company has a market cap of $60.82 million, a P/E ratio of -1.90 and a beta of 0.51.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company had revenue of $9.89 million during the quarter, compared to the consensus estimate of $9.73 million. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. During the same period last year, the business posted ($0.14) EPS. As a group, analysts anticipate that Cytosorbents will post -0.32 EPS for the current year.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.